This is a news story, published by Yahoo Finance, that relates primarily to Amtagvi news.
For more Amtagvi news, you can click here:
more Amtagvi newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
new cancer drug Amtagvi. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Iovance Biotherapeutics Shares news, veteran biopharma investors none news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Iovance BiotherapeuticsThe Motley Fool
•72% Informative
Shares of Iovance Biotherapeutics are up 24.2% as of 11:20 a.m. ET today in response to an impressive second-quarter report.
The company's new cancer drug Amtagvi (also known as lifileucel) is off to a solid start.
The potential for the drug is enormous; researchers with Global Data suggest it could be producing annual sales of more than $800 million by 2029 .
VR Score
69
Informative language
71
Neutral language
32
Article tone
semi-formal
Language
English
Language complexity
49
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
7
Source diversity
2
Affiliate links
no affiliate links